BIO-Europe Spring 2017 to be held in Barcelona from March 20 to 22

More than 2,400 senior executives from 1,400+ leading international biotech companies, pharmaceutical companies, investors and business development team members will attend this annual event, which will be held this year in a biotech hub known for its entrepreneurship and innovative approaches to the challenges of research and development in the industry.

Known as the BioRegion, the health and life sciences cluster in the Catalonia region of Spain is made up of 824 companies - 241 biotech, 51 pharma, 83 innovative medical technology, 217 suppliers and engineering firms, 133 consulting and professional services, 70 eHealth companies and 29 active investment organizations , 89 research bodies and facilities - 41 research centers, 15 university hospitals, 11 universities, 2 large-scale facilities,  7 technology centers and 13 science and technology parks (Source: Biocat Directory, December 2016).

Between 2015 and 2016, companies in the BioRegion of Catalonia attracted more than EUR €151 million in investment. Catalonia is also the 4th European country in biotechnology companies per capita. (Source: Biocat Directory, December 2016).

"With a population of more than 7.5 million and territory comparable to that of European countries like Finland, Belgium, and the Netherlands, Catalonia has the most dynamic life sciences cluster in Spain and one of the most active in southern Europe," said Dr. Albert Barberà, CEO of Biocat. "Biocat encourages all the stakeholders of the BioRegion, including companies, research groups and entities, hospitals and innovation support structures to transform knowledge and technology into economic growth and to create a social impact."

"BIO-Europe Spring is the most significant industry event of the new year where top executives from global biotech, pharma and finance come together to access hundreds of potential partners to make their companies' collaborative goals a reality," said Anna Chrisman, group managing director, EBD Group.

One-to-one partnering meetings facilitated by EBD Group's partneringONE are a key business strategy that have transformed the drug development industry by facilitating collaboration between innovators and biopharma executives from every corner of the globe. Company presentations by early stage projects, innovative startups, established biotechs and midsize pharma companies are also a focus of the event and enable innovators to present directly to potential investors, pharma and development partners.

Some of the high-profile pharmaceutical companies that attended BIO-Europe Spring 2016, held in Stockholm, Sweden, included AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, MSD, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda and others.

BIO-Europe Spring 2016 featured 12,452 one-to-one meetings, 3,129 licensing opportunities, 2,373 attendees, 1,377 companies, 124 company presentations, 68 exhibitors, 49 countries participation.

Registration information for BIO-Europe Spring is available online. Register before January 20, 2017 to save EUR 200 off the regular registration rate.

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
 

Bio-europe, barcelona